2017-09-27 Pharma Scoop: Nektar’s potential, Axovant Finally Fails, PTCT AdComm Tomorrow
- Nektar’s strategy shifting and potential is discussed.
- Axovant finally did what it was supposed to do - failed.
- PTC Therapeutics has an adcomm for its DMD drug tomorrow.
Analysis of top Seeking Alpha coverage: Nektar Therapeutics
Today’s coverage is Nektar Therapeutics Building A More Exciting Pipeline by Stephen Simpson, CFA. The author is covering Nektar Therapeutics (NKTR), a leader in PEGylation technology and a company I like, myself. Nektar’s ageing technology once pioneered this niche, and held sway for more than 15 years, with most PEGylated drugs from big pharma coming from Nektar’s technology. As such, the company made money from licensing. It also had its own product pipeline, some of which have been quite successful. Lately, some of its royalty-generating drugs have begun to go off-shelf, and Nektar has tried hard to reinvent itself as a standard therapeutics company. As the author says, “As Nektar (NKTR) has gotten investors more excited about its pipeline, including a somewhat surprising success with its late-stage pain drug NKTR-181, the shares have done all right since the fall of 2016 – rising more than a third since then (in line with the SPDR S&P Biotech (XBI) and ahead of the iShares Nasdaq Biotechnology (IBB)).”
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.